Validation of a novel approach for dose individualization in pharmacotherapy using gabapentin in a proof of principles study

Pharmacotherapy

Volumn 33, Issue 7, 2013, Pages 727-735

  Blau, Gary E ^a   Orcun, Seza ^b   Laínez, José M ^a   Reklaitis, Gintaras V ^a   Suvannasankha, Attaya ^c   Fausel, Chris ^c   Anaissie, Elias J ^d  

^a PURDUE UNIVERSITY   (United States)

^b Seza Orcun Consulting Services   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Dose individualization; Gabapentin treatment; Pharmacokinetics; Risk management; Therapeutic drug monitoring

Indexed keywords

GABAPENTIN;

ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DRUG ABSORPTION; DRUG EFFECT; DRUG ELIMINATION; DRUG TRANSPORT; HUMAN; INDIVIDUALIZED DOSING CHART; MAXIMUM PLASMA CONCENTRATION; MEDICAL DECISION MAKING; MEDICAL PROCEDURES; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OPTIMAL SAMPLING SCHEDULE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; TREATMENT PLANNING; URINARY EXCRETION; VALIDATION PROCESS;

DOSE INDIVIDUALIZATION; GABAPENTIN TREATMENT; PHARMACOKINETICS; RISK MANAGEMENT; THERAPEUTIC DRUG MONITORING;

AMINES; ANALGESICS; BAYES THEOREM; CYCLOHEXANECARBOXYLIC ACIDS; DECISION SUPPORT TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; GAMMA-AMINOBUTYRIC ACID; HUMANS; INDIVIDUALIZED MEDICINE; POINT-OF-CARE SYSTEMS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 84885415457     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1267     Document Type: Article

References (20)

1. McLean MJ. Gabapentin in the management of convulsive disorders. Epilepsia 1999;40:S39-50.
2. Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther 2003;25:81-204.
3. Rowbothan M, Hardin N, Stacey B, Bernstein P, Magnus- Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998;280:1837-42.
4. Goa KL, Sorkin EM. Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy. Drugs 1993;46:409-27.
5. McLean MJ. Clinical pharmacokinetics of gabapentin. Neurology 1994;44:S17-22.
6. Gidal BE, Radulovic LL, Kruger S, Rutecki P, Pitterle P, Bockbrader HN. Inter-intra subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Res 2000;40:123-7.
7. A Park Davis, a Division of Pfizer. Neurotin (gabapentin) package insert. New York, NY; 2009.
8. ARUP-Laboratory Test Directory. Gabapentin. Available from http://www.aruplab.com/guides/ug/tests/0090056.jsp. Accessed March 22, 2012.
9. Garcia LL, Shihabi ZK, Oles ZA. Determination of gabapentin in serum by capillary electrophoresis. J Chromatogr B Biomed Sci Appl 1995;669:157-62.
10. U.S. News Health. Personalized medicine overview. Available from http://health.usnews.com/health-conditions/cancer/ personalized-medicine. Accessed March 22, 2012.
11. Neely M, Jelliffe R. Practical, individualized dosing: 21st century therapeutics and the clinical pharmacometrician. J Clin Pharmacol 2010;50:842-7.
12. Neely M, Jelliffe R. Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization. J Clin Pharmacol 2008;48:1081-91.
13. Jelliffe R, Schumitzky A, van Guilder M, et al. Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control. Ther Drug Monit 1993;15:380.
14. Blau G, Lasinski M, Orcun S, et al. High fidelity mathematical model building with experimental data: a Bayesian approach. Comput Chem Eng 2008;32:971-89.
15. Hsu S, Stamatis S, Caruthers J, et al. Bayesian framework for building kinetic models of catalytic systems. Ind Eng Chem Res 2009;48:4768-90.
16. Lainez JM, Blau G, Mockus L, Orcun S, Reklaitis GV. Pharmacokinetic based design of individualized dosage regimens using a Bayesian approach. Ind Eng Chem Res 2011;50:5114-30.
17. Urban TJ, Brown C, Castro RA, et al. Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. Clin Pharmacol Ther 2008;83:416-21.
18. Gilks WS, Richardson S, Spiegelhalter D. Markov chain Monte Carlo in practice. Boca Raton, FL: Chapman & Hall, CRC Press 1996.
19. Lainez JM, Mockus L, Orcun S, Blau G, Reklaitis GV. A decomposition strategy for the variational inference of complex systems. Technometrics 2012(submitted for publication).
20. Mallet A. A maximum likelihood estimation method for random coefficient regression models. Biometrika 1986;73: 645-56.